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vivo study. Toll-like receptor (TLR)-stimulated human PBMCs
or murine bone marrow-derived dendritic cells were used for
in vitro study.
Results Our study demonstrated that DZ2002 exerted a thera-
peutic effect on NZB/W F1 mice with established nephritis.
The mechanism involves the modulation of T cell development
in lupus by interfering with TLR-triggered APC function. Fur-
ther study explored the regulatory mechanisms of SAHH on
DC function in both innate and adaptive immune system,
using the SAHH inhibitor with definite target and potent
immunosuppressive activity.
Conclusions The present issue demostrated that the reversible
SAHH inhibitor DZ2002 effectively ameliorates lupus syn-
drome in NZB/W F1 mice by regulating TLR signaling-medi-
ated APC responses. This compound is prospective to become
a novel drug for SLE treatment with Hcy as a potential bio-
marker in autoimmune disease.
108 IGURATIMOD INHIBITS HUMAN B CELL TERMINAL
DIFFERENTIATION IN VITRO AND MAY BENEFIT
PATIENTS WITH REFRACTORY LUPUS NEPHRITIS
1Q Yan*, 1Y Ye, 2X Zhang, 1C Bao. 1RenJi Hospital- School of Medicine- Shanghai JiaoTong
University, Rheumatology, Shanghai, China; 2Chinese Academy of Sciences, Institute Pasteur
of Shanghai, Shanghai, China
10.1136/lupus-2017-000215.108
Background and Aims Iguratimod (IGT) is a small molecular
immunomodulatory drug and has been approved for treating
rheumatoid arthritis. In our previous work, IGT ameliorates
lupus-like disease in MRL/lpr mice by inhibiting abnormal B
cell differentiation. The aim of this study is to further investi-
gate the effects of IGT on human B cells.
Methods We established a set of stimulations to induce naive
human B cell into plasmablast (PB) in vivo. We also enrolled
7 patients with refractory lupus nephritis (LN) to assess the
potential efficacy of IGT.
Results IGT significantly attenuates the generation of CD19
+CD20-CD27hiCD38hi plasma cells upon both BCR-depend-
ent and independent stimulations. IGT affects neither prolifera-
tion or apoptosis of B cell in vitro. In further investigation on
B cell differentiation signalling pathwasys, we identifies that
Blimp-1 and Xbp-1 can be remarkably impaired by IGT both
in transcriptional and protein level; while Jak/STAT or NF-kB
signalling are intact with IGT treatment. For explosive clinical
study, seven patients with refractory LN were enrolled and
administrated with IGT and steroids. ALL of these patients
surprisingly show improved proteinuria after 8 week treat-
ment. One patient quit the treatment because of anaemia.
Conclusions IGT has a unique effect to arrest B cell terminal
differentiation, which provides strong evidence that this drug
could be a new candidate drug to treat B cell related autoim-
mune diseases such as lupus.
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Background and aims Preliminary data suggested efficacy of
sirolimus in treatment of lupus nephritis (LN), but its long-
term efficacy and tolerability data is lacking.
Methods We reviewed Class III/IV/V LN patients who received
prednisolone and sirolimus either as initial or maintenance
treatment during Jan 2007 to Jan 2016.
Results Sixteen patients were included (duration of sirolimus
treatment: 27.2±19.6 months). Ten patients received sirolimus
due to intolerance to standard immunosuppressive treatments
and six patients because of a history of malignancy. Five
patients received sirolimus during active LN, and showed
improvement in proteinuria (2.8±1.9 g/day and 0.1±0.1 g/day
at baseline and 36 months, p=0.011 compared to baseline),
anti-dsDNA (107.7±91.9 IU/mL and 37.0±55.4 IU/mL at
baseline and 36 months, p=0.145) and C3 (54.8±26.1 mg/dL
and 86.3±18.6 mg/dL at baseline and 36 months, p=0.084).
Eleven patients received sirolimus during disease quiescence,
and showed significant improvement in C3 (90.4±18.1 mg/dL
and 117.7±25.1 mg/dL at baseline and 36 months, p=0.025)
and stable renal function (58.5±25.2 ml/min and 56.7
±29.0 mL/min at baseline and 36 months, p=0.199) and pro-
teinuria (0.8±0.7 g/day and 0.7±0.7 g/day at baseline and 36
months, p=0.263). One patient, whose serum creatinine was
244 mmol/L when sirolimus was started, developed renal fail-
ure after 27 months. Renal flare occurred in one patient after
36 months. Sirolimus was discontinued in five patients includ-
ing one with leucopenia. Four patients showed lipid profile
deterioration which was adequately controlled with statin.
Conclusions Sirolimus can be an alternative treatment option
for LN and the long-term results do not suggest excessive
adverse effects.
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Background and aims We report the case of a 62-year-old
woman. Psoriasis Vulgaris (Psoriasis) was diagnosed in X-31
year and also SLE with nephritis (WHO IIIA) in X-11. She
was treated with high-dose methylprednisolone and cyclospor-
ine A (CsA) to achieve remission. Methylprednisolone was
reduced to 4 mg/day.
Methods Because of renal dysfunction, although CsA was dis-
continued in May X, psoriasis, renal dysfunction and protei-
nuria became further worse, she was admitted to hospital in
July X. She was diagnosed with SLE flare with class IV-G(A/
C)+V lupus nephritis (INS/RPS) and associated psoriasis. The
SLEDAI score was 16 and psoriasis area and severity index
(PASI) score was 16. Although high-dose corticosteroid (1 mg/
kg/day) and a concomitant first dose of IV cyclophosphamide
(IVCY) were started, anasarca was still observed and S-Cr was
increased from 1.98 to 2.85 mg/dL. Because proportion of
activated Th17 cells were increased in peripheral blood(PD),
and the infiltration of many lymphocytes and IL-17-positive
cells in renal interstitium, secukinumab, an antibody against
IL-17A, was administered.
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